دورية أكاديمية
Osteopontin as a tumor marker in ovarian cancer
| العنوان: | Osteopontin as a tumor marker in ovarian cancer |
|---|---|
| المؤلفون: | Shikha Rani, Alka Sehgal, Jasbinder Kaur, Dilpreet Kaur Pandher, Rajpal Singh Punia |
| المصدر: | Journal of Mid-Life Health, Vol 13, Iss 3, Pp 200-205 (2022) |
| بيانات النشر: | Wolters Kluwer Medknow Publications, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Gynecology and obstetrics LCC:Geriatrics |
| مصطلحات موضوعية: | carbohydrate antigen-125, osteopontin, ovarian cancer, tumor marker, Gynecology and obstetrics, RG1-991, Geriatrics, RC952-954.6 |
| الوصف: | Introduction: Ovarian cancer is associated with high morbidity and mortality. This is due to the nonspecific symptoms and no effective screening methods. Currently, carbohydrate antigen-125 (CA125) is used as a tumor biomarker for the diagnosis of ovarian cancer, but it has its own limitations. Hence, there is a need for other tumor biomarkers for the diagnosis of ovarian cancer. Objective of the study was to evaluate the diagnostic test characteristics of plasma osteopontin (OPN) in detecting ovarian malignancy and comparing its performance with CA125. Materials and Methods: This is a prospective cross-sectional diagnostic test evaluation. Women with adnexal mass detected by clinical or radiological examination were enrolled as suspected cases. Women who presented with other gynecological conditions were enrolled as controls. OPN and CA125 levels were measured in all enrolled subjects. Results: Among 106 women enrolled, 26 were ovarian cancer, 31 had benign ovarian masses, and 49 were controls. Median plasma CA125 levels were higher in subjects with ovarian cancer (298 U/ml; interquartile range [IQR]: 84–1082 U/ml vs. 37.5U/ml; IQR: 17.6–82.9U/ml; P < 0.001). CA125 sensitivity, specificity, positive, and negative likelihood ratios were 88.5%, 61.3%, 2.10, and 0.19, respectively. Median plasma OPN levels were higher in subjects with ovarian cancer (63.1 ng/ml; IQR: 39.3–137 ng/ml vs. 27 ng/ml; IQR: 20–52 ng/ml; P = 0.001). Sensitivity, specificity, positive, and negative likelihood ratios of OPN were 50%, 87%, 2.58, and 0.62, respectively. Conclusion: OPN levels were higher in ovarian cancer than in the benign ovarian mass and had better specificity than CA125. OPN can better differentiate between benign and malignant ovarian mass as compared to CA125. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 0976-7800 0976-7819 |
| Relation: | http://www.jmidlifehealth.org/article.asp?issn=0976-7800;year=2022;volume=13;issue=3;spage=200;epage=205;aulast=Rani; https://doaj.org/toc/0976-7800; https://doaj.org/toc/0976-7819 |
| DOI: | 10.4103/jmh.jmh_52_22 |
| URL الوصول: | https://doaj.org/article/9c78957a3b53475c8b5f7dd7e7387094 |
| رقم الأكسشن: | edsdoj.9c78957a3b53475c8b5f7dd7e7387094 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 09767800 09767819 |
|---|---|
| DOI: | 10.4103/jmh.jmh_52_22 |